Finally, it should be noted that HLA-I/CD8+ T cell dysfunction would adversely affect an otherwise positive outcome of the peptide-based cancer vaccines (discussed below), a therapy that would profit from a concomitant ICI therapy, as has been observed [54]. This evidence concerns the gene CD8A and cancer.